A Phase 4 interventional study of Anticoagulant in Atrial Fibrillation, sponsored by InCor Heart Institute. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-01.
Sponsored by InCor Heart Institute · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Atrial Fibrillation with a site in Brazil — 10 open to participants now, 12 under way, 4 of them phase 3. Atrial Fibrillation · Brazil.
Among the 56 studies in Atrial Fibrillation with a site in Brazil, this one is the 23rd largest by planned enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2015, is one of 9 in phase 4, reaches primary completion later than 0 of the 11 other live ones, and was the 24th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →10 of the 56 studies in Atrial Fibrillation with a site in Brazil are open now. Recruiting first, the newest first:
Javelin Medical · Sites in Brazil, United States, Canada and 1 more country
Ages 18+
Regeneron Pharmaceuticals · Sites in Brazil, United States, Argentina and 1 more country
Ages 18+
Abbott Medical Devices · Sites in Brazil, France, Germany and 6 more countries
Ages 18+
University of Sao Paulo · Sites in Brazil
Ages 22+
Hospital Sirio-Libanes · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 26 · Phase 4 9
First in 1995; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,054 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 1,504 across the 49 interventional studies, 833 across the 7 observational. Of the 39 that completed or were terminated, 21 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 56 have an industry lead sponsor. The 10 most frequent:
InCor Heart Institute is the lead sponsor of 27 studies on the registry; 4 are open to participants now.
InCor Heart Institute has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
4 of the studies in Atrial Fibrillation with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT06402851Hospital Sirio-LibanesVitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE) | 2026-12 |
| NCT07175428Regeneron PharmaceuticalsSafety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | 2027-02-09 |
| NCT07217392Abbott Medical DevicesLeft Bundle Branch Area Pacing (LBBAP) PMCF Study | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Atrial Fibrillation with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Introduction: Patients with atrial fibrillation (AF) have a substantial risk of stroke and systemic embolism. Subclinical AF is often suspected to be the cause of stroke in these patients. The detection of asymptomatic AF episodes is a challenge and the real rate of occurrence of these episodes remains unknown. The rate of stroke is high among patients who have received a pacemaker and this device can detect subclinical episodes of rapid atrial rate, which correlate with electrocardiographically documented AF. The net benefit of anticoagulant treatment is well established in patients with clinical AF but data about anticoagulation in subclinical AF setting is unknown. The aim of this study is to assess the impact of anticoagulant therapy on subclinical AF, directed by cardiac implantable electronic device (CIED) intensive monitoring, on the incidence of stroke and systemic embolism and correlate the AF episodes detected by CIED with thromboembolic events. Methods: This is a prospective, randomized, unicentric, parallel clinical study in patients with atrioventricular pacemaker, defibrillator, or cardiac resynchronization therapy devices in sinus rhythm and CHADS2 score (an index of the risk of stroke in patients with atrial fibrillation, range from 0 to 6) ≥ 2 . Patients will be randomized to the intervention group - intensive monitoring arm (Group I) or control group - routine schedule arm (Group II) in a 1:1 ratio. Time to inclusion will be 24 months and all patients will be followed up for a period of 36 months. Group I, patients will be submitted to device data collection every 2 months, while in Group II, patients will be managed conventionally. Patients from Group I with episodes of subclinical AF will receive anticoagulant therapy, as well as patients with clinical AF of both arms. Device data from Group II patients will not be analyzed until they achieve the primary endpoint. Primary endpoint: stroke or systemic embolism. Secondary endpoints: subclinical AF rate, total mortality, cardiovascular mortality, myocardial infarction, cardiovascular hospitalization, and bleeding rates. Expected outcome: It is expected that anticoagulation therapy of subclinical AF directed by CIED intensive monitoring will reduce the incidence of stroke and systemic embolism comparing to patients with non-diagnosed subclinical AF.
Patients with atrial fibrillation (AF) have a substantial risk of stroke and systemic embolism. Subclinical AF is often suspected to be the cause of stroke in these patients. The detection of asymptomatic AF episodes is a challenge and the real rate of occurrence of these episodes remains unknown. The rate of stroke is high among patients who have received a pacemaker and this device can detect subclinical episodes of rapid atrial rate, which correlate with electrocardiographically documented AF. The net benefit of anticoagulant treatment is well established in patients with clinical AF but data about anticoagulation for subclinical AF settings is unknown. The aim of this study is to assess the impact of anticoagulant therapy on subclinical AF, directed by cardiac implantable electronic device (CIED) intensive monitoring, on the incidence of stroke and systemic embolism and correlate the AF episodes detected by CIED with thromboembolic events. Methods: This is a prospective, randomized, unicentric, parallel clinical study in patients with an atrioventricular pacemaker, defibrillator, or cardiac resynchronization therapy devices in sinus rhythm and CHADS2 score (an index of the risk of stroke in patients with atrial fibrillation, range from 0 to 6) ≥ 2 . Patients will be randomized to the intervention group - intensive monitoring arm (Group I) or control group - routine schedule arm (Group II) in a 1:1 ratio. Time to inclusion will be 24 months and all patients will be followed up for a period of 36 months. Group I, patients will be submitted to device data collection every 2 months, while in Group II, patients will be managed conventionally. Patients from Group I with episodes of subclinical AF will receive anticoagulant therapy, as well as patients with clinical AF of both arms. Device data from Group II patients will not be analyzed until they achieve the primary endpoint. Primary endpoint: stroke or systemic embolism. Secondary endpoints: subclinical AF rate, total mortality, cardiovascular mortality, myocardial infarction, cardiovascular hospitalization, and bleeding rates. Expected outcome: It is expected that anticoagulation therapy of subclinical AF directed by CIED intensive monitoring will reduce the incidence of stroke and systemic embolism comparing to patients with non-diagnosed subclinical AF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prescription of oral anticoagulation for patients with silent AF (detected by the pacemaker).
Drug: Anticoagulant
Patients with silent FA detected only by the pacemaker will no receive oral anticoagulation.
Anticoagulant treatment will be started in case of subclinical atrial fibrillation (\>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
Also known as: Oral Anticoagulant
Stroke
Occurrence of stroke
Time frame: 36 months
Systemic embolism
Occurrence of systemic embolism
Time frame: 36 months
Subclinical AF rate
Rate subclinical AF documentation by pacemaker
Time frame: 36 months
Total mortality
All cause mortality
Time frame: 36 months
Cardiovascular mortality
Adjudicated cardiovascular mortality
Time frame: 36 months
Myocardial infarction
Occurrence of myocardial infarction
Time frame: 36 months
Cardiovascular hospitalization
Adjudicated cardiovascular hospitalization
Time frame: 36 months
Bleeding rates
Occurrence of bleeding
Time frame: 36 months
Started Feb 2015 (actual). Primary completion is estimated for Oct 2025, 128 months after the start.
Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 128 months is above that.
Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InCor Heart Institute